High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations

Exogenous Aβ1-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice

(2022) Yanhong Duan et al.   NEUROPHARMACOLOGY

Soluble Amyloid-β Consumption in Alzheimer’s Disease

(2021) Alberto J. Espay et al.   JOURNAL OF ALZHEIMERS DISEASE

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study

(2021) Anne M Fagan et al.   LANCET NEUROLOGY

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

APP Osaka Mutation in Familial Alzheimer’s Disease—Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance

(2020) Takami Tomiyama et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Kinetic diversity of amyloid oligomers

(2020) Alexander J. Dear et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology

(2020) Maja Malmberg et al.   Frontiers in Neuroscience

The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics

(2020) Sarah A. Kent et al.   ACTA NEUROPATHOLOGICA

Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?

(2019) Francesco Panza et al.   ANNALS OF NEUROLOGY

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

(2018) Eric McDade et al.   NEUROLOGY

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase

(2016) Linfeng Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Partial volume correction in quantitative amyloid imaging

(2015) Yi Su et al.   NEUROIMAGE

Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases

(2015) Prajwal Ciryam et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome

(2014) Erik Portelius et al.   NEUROMOLECULAR MEDICINE

Methods for estimating relative risk in studies of common binary outcomes

(2013) Alok Kumar Dwivedi et al.   JOURNAL OF APPLIED STATISTICS

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Increased in Vivo Amyloid- 42 Production, Exchange, and Loss in Presenilin Mutation Carriers

(2013) R. Potter et al.   Science Translational Medicine

Widespread Aggregation and Neurodegenerative Diseases Are Associated with Supersaturated Proteins

(2013) Prajwal Ciryam et al.   Cell Reports

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

(2013) Gaël Chételat et al.   NeuroImage-Clinical

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores

(2008) Sid E. O’Bryant   ARCHIVES OF NEUROLOGY